Synthesis, molecular docking, and biological testing of new selective inhibitors of glycogen synthase kinase 3β

[1]  R. Jope,et al.  Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics , 2007, Neurochemical Research.

[2]  H. Manji,et al.  Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. , 2006, Current drug targets.

[3]  T. Gould.  Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications , 2006, Expert opinion on therapeutic targets.

[4]  H. Eldar-Finkelman.  Glycogen synthase kinase-3--a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Emma Quigley. , 2006, Expert opinion on therapeutic targets.

[5]  A. Ougolkov,et al.  Targeting GSK-3: a promising approach for cancer therapy? , 2006, Future oncology.

[6]  H. Pertz,et al.  New Oxadiazole Derivatives Showing partly Antiplatelet, Antithrombotic and Serotonin Antagonistic Properties , 2005, Archiv der Pharmazie.

[7]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[8]  S. Knapp,et al.  Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. , 2003, Journal of molecular biology.

[9]  A. A. Santilli,et al.  SYNTHESIS OF 3‐ARYLSULFONYLMETHYL‐1,2,4‐OXADIAZOLE‐5‐CARBOXYLIC ACID DERIVATIVES , 1979 .

[10]  R. Howe,et al.  Periselective addition of nitrile sulfides, nitrile oxides and diphenyldiazomethane to tetracyanoethylene , 1976 .

[11]  I. Kay,et al.  Chloro (ethoxycarbonyl)methyleneiminium salts - versatile electrophilic intermediates for heterocyclic synthesis , 1979 .